Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
This study has been completed.
Sponsor:
Celgene Corporation
Information provided by:
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT00657488
First received: April 7, 2008
Last updated: September 22, 2008
Last verified: September 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | April 2006 |
| Primary Completion Date: | October 2005 (Final data collection date for primary outcome measure) |